Login or sign up
For business

Corcept therapeutics

4.1ยท 12 reviews
Average ratingGreat
4.1/ 5

Based on 12 reviews

542%
425%
333%
20%
10%
Jason Hochman
Reviews 1

Corcept Therapeutics is truly amazing! Their dedication to providing effective medical solutions is unparalleled. I am extremely impressed with their commitment to innovation and high-quality products. The company website, corcept.com, is user-friendly and informative, making it easy to navigate and find all the necessary information. Overall, Corcept Therapeutics is a company that I highly recommend!

James Friedman
Reviews 1

Corcept Therapeutics is a company that truly understands patient needs. They have a wide range of innovative and effective medical solutions. The website, corcept.com, provides detailed information about their products and services. I am extremely satisfied with their offerings!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website โ€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Corcept therapeutics

Corcept is a leader in the research and development of cortisol modulators. Learn more about our work, products, and commitment to patients.

Corcept Therapeutics: Leading the Way in Cortisol Modulation

Corcept Therapeutics is a biopharmaceutical company that specializes in the research and development of cortisol modulators. The company was founded in 1998 by Dr. Joseph K. Belanoff, who recognized the potential of cortisol modulation as a treatment for a variety of medical conditions.

Cortisol is a hormone produced by the adrenal gland that plays an important role in regulating metabolism, immune function, and stress response. However, excess cortisol production can lead to a range of health problems, including Cushing's syndrome and major depressive disorder.

Corcept's flagship product is Korlym (mifepristone), which was approved by the FDA in 2012 for the treatment of hyperglycemia secondary to Cushing's syndrome. Korlym works by blocking the action of cortisol at its receptor sites, thereby reducing symptoms such as weight gain, high blood pressure, and glucose intolerance.

In addition to Korlym, Corcept has several other products in development that target different aspects of cortisol regulation. These include relacorilant (formerly known as CORT125134), which is being studied for its potential use in treating patients with Cushing's syndrome who have failed surgery or are not candidates for surgery; and exicorilant (formerly known as CORT118335), which is being developed as a treatment for patients with metastatic castration-resistant prostate cancer.

One key advantage of Corcept's approach to drug development is its focus on precision medicine. By identifying specific patient populations that are most likely to benefit from their products based on genetic markers or other biomarkers, Corcept can tailor their treatments to individual patients' needs more effectively than traditional one-size-fits-all approaches.

Another important aspect of Corcept's work is their commitment to patient advocacy and education. The company maintains an active presence on social media platforms such as Twitter and LinkedIn where they share news about their research progress and engage with patients and healthcare professionals alike.

Overall, Corcept Therapeutics represents an exciting frontier in biopharmaceutical research with enormous potential for improving patient outcomes across multiple disease areas related to cortisol dysregulation. With innovative products like Korlym already making a significant impact on patient care today and promising new therapies on the horizon tomorrow, it's clear that this company will continue leading the way forward into an exciting future full of possibilities!

Address
149 commonwealth drive
Categories
Pharmaceuticals